A new treatment for Idiopathic Pulmonary Fibrosis using a bispecific antibody.
A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis
This study is testing a new treatment called VTC-890 that aims to help people with Idiopathic Pulmonary Fibrosis by blocking two proteins that cause lung scarring, with the hope of improving their breathing and overall health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virtici, LLC NIH-funded |
| Lab location | 1 site (Seattle, UNITED STATES) |
| Project ID | NIH-11116876 on NIH RePORTER |
What this research studies
This research focuses on developing a bispecific antibody called VTC-890 that targets two inflammatory proteins involved in Idiopathic Pulmonary Fibrosis (IPF). By blocking these proteins, the treatment aims to reduce lung tissue scarring and improve lung function in patients suffering from this chronic disease. The approach is based on understanding the complex interactions of cytokines that contribute to the progression of IPF. Patients may be monitored for changes in lung function and overall health as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis who are experiencing declining lung function.
Not a fit: Patients with other forms of lung disease or those who do not have a diagnosis of Idiopathic Pulmonary Fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that significantly slows the progression of Idiopathic Pulmonary Fibrosis.
How similar studies have performed: While there have been advancements in antifibrotic treatments for IPF, the specific approach of using a bispecific antibody like VTC-890 is novel and has not been extensively tested in this context.
Where this research is happening
Seattle, UNITED STATES
- Virtici, LLC — Seattle, United States (Active)
Researchers
- Principal investigator: Fanger, Neil a — Virtici, LLC
- Study coordinator: Fanger, Neil a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.